## Core Concept
The question pertains to the concept of enzyme inhibition, specifically focusing on competitive inhibition. **Competitive inhibition** occurs when an inhibitor molecule closely resembles the substrate and competes with it for binding to the **active site** of the enzyme. This type of inhibition can be overcome by increasing the concentration of the substrate.

## Why the Correct Answer is Right
The correct answer, , represents a scenario where the inhibitor competes with the substrate for the active site on the enzyme. This is characteristic of competitive inhibition, where the **Km (Michaelis constant)** appears to increase (since it takes a higher substrate concentration to achieve half-maximal velocity due to competition), but the **Vmax (maximum velocity)** of the enzyme remains unchanged. Increasing the substrate concentration can outcompete the inhibitor, allowing the enzyme to reach its Vmax.

## Why Each Wrong Option is Incorrect
- **Option A:** - This option does not accurately describe competitive inhibition. Non-competitive inhibition involves the inhibitor binding to an allosteric site, changing the enzyme's shape, and affecting its activity without competing with the substrate for the active site.
- **Option B:** - This option seems to suggest a mixed or uncompetitive type of inhibition, which is not the focus of the question. Uncompetitive inhibition involves the inhibitor binding to the enzyme-substrate complex, reducing both Km and Vmax.
- **Option D:** - This option might imply a scenario that doesn't fit the classic definition of competitive, non-competitive, or uncompetitive inhibition.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **competitive inhibitors** can be overcome by increasing the substrate concentration. This is clinically relevant in scenarios such as the use of **methotrexate** (a folate antagonist used in cancer chemotherapy and autoimmune diseases), where **folinic acid (leucovorin)** can be administered to rescue normal cells by providing an alternative source of folate that does not compete with methotrexate.

**Correct Answer: .**